IQ行业视角:肾功能不全患者给药建议的制定
调查发现各公司评估肾功能的方法不统一,但基于模型的预测方法(如群体PK、PBPK和虚拟对照)显著改善了对肾功能影响药物PK的预测,使更多肾功能不全患者参与2期和3期试验。
要点
- 各制药公司评估肾功能的方法不一致。
- 基于模型的预测方法能更早预测肾功能对PK的影响。
- 预测改善使更多肾功能不全患者参与2期和3期试验。
核心结论
- 制药公司评估肾功能的方法不一致,但基于模型的预测方法显著改善了对肾功能影响PK的预测。
主要发现
- 各公司评估肾功能的方法不一致。
- 基于模型的预测方法(群体PK、PBPK、虚拟对照)能更早预测肾功能对PK的影响,使更多肾功能不全患者参与2期和3期试验。
临床怎么用
- 临床药学智能体医生可关注基于模型的预测方法在肾功能不全患者给药建议制定中的应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The IQ CPLG Organ Impairment WG conducted a survey to understand how various IQ member companies develop dosing recommendations for patients with renal impairment. Eighteen IQ member companies participated in the survey. The survey results were summarized by the working group in light of the regulatory renal impairment guidance documents as well as recent publications from the pharmaceutical industry and nephrology community. There were two important learnings from the survey: (i) pharmaceutical companies do not use a consistent methodology to assess renal function in their drug development programs. (ii) there has been significant improvement in predicting how kidney function affects drug pharmacokinetics (PK) and thus dose recommendations. Applying model-based methods such as population PK, physiologically-based PK (PBPK), and virtual controls has enabled earlier prediction of how kidney function influences PK, leading to the participation of more patients with impaired kidney function in Phase 2 and 3 trials.
引用
- Sharma A, Younis IR, Kanodia J, et al. An IQ Industry Perspective on Informing Dosing Recommendations in Patients With Renal Impairment. Clin Pharmacol Ther. 2024. PMID: 39439185. doi:10.1002/cpt.3463
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。